Original Articles
Vol. 12 (2017)
https://doi.org/10.3269/1970-5492.2017.12.21

ROLE OF HEME OXYGENASE-1 (HSP32) AND HSP90 IN GLIOBLASTOMA.

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Received: October 24 2025
Published: January 12 2026
133
Views
69
Downloads

Authors

Carlo Castruccio Castracani
Department of Biomedical and Biotechnological Sciences, University of Catania, Catania (Italy);, Italy.
Michelino Di Rosa
Department of Biomedical and Biotechnological Sciences, University of Catania, Catania (Italy);, Italy.
Pio Maria Furneri
Department of Biomedical and Biotechnological Sciences, University of Catania, Catania (Italy);, Italy.
Roberto Avola
Department of Biomedical and Biotechnological Sciences, University of Catania, Catania (Italy);, Italy.
Daniele Tibullo
Department of Biomedical and Biotechnological Sciences, University of Catania, Catania (Italy);, Italy.
Giovanni Li Volti
livolti@unict.it
Department of Biomedical and Biotechnological Sciences, University of Catania, Catania (Italy);, Italy.
Francesca Rappa
Department of Experimental Biomedicine and Clinical Neurosciences, University of Palermo, Palermo (Italy), Italy.
Tiziana Bono
Fondazione Istituto G. Giglio di Cefalù, Cefalù (PA), Italy, Italy.

Glioblastoma (GBM) is the most common and malignant primary brain tumor in adults. The current treatment regimes for glioblastoma demonstrated a low efficiency and offer a poor prognosis.Advancements in conventional treatment strategies have only yielded modest improvements in overall survival. The heat shockproteins, heme oxygenase-1 (HO-1) and Hsp90, serve these pivotal roles in tumor cells and have been identified as effective targets for developing therapeutics. This topic review summarizes the current preclinical and clinical evidences and rationale to define the potential of HO-1 and Hsp90 in GBM progression and chemoresistance.

Downloads

Download data is not yet available.

How to Cite



ROLE OF HEME OXYGENASE-1 (HSP32) AND HSP90 IN GLIOBLASTOMA. (2026). EuroMediterranean Biomedical Journal, 12. https://doi.org/10.3269/1970-5492.2017.12.21
Copyright (c) 2026 The Author(s) Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.